Iterum Therapeutics PLC (ITRM) - Total Assets
Based on the latest financial reports, Iterum Therapeutics PLC (ITRM) holds total assets worth $32.50 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Iterum Therapeutics PLC - Total Assets Trend (2016–2024)
This chart illustrates how Iterum Therapeutics PLC's total assets have evolved over time, based on quarterly financial data. Also see Iterum Therapeutics PLC (ITRM) market capitalisation for the company's overall valuation and market capitalisation.
Iterum Therapeutics PLC - Asset Composition Analysis
Current Asset Composition (December 2024)
Iterum Therapeutics PLC's total assets of $32.50 Million consist of 55.6% current assets and 44.4% non-current assets. Review Iterum Therapeutics PLC (ITRM) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 54.1% |
| Accounts Receivable | $66.00K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $19.75 Million | 44.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Iterum Therapeutics PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Iterum Therapeutics PLC for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Iterum Therapeutics PLC's current assets represent 55.6% of total assets in 2024, a decrease from 96.1% in 2016.
- Cash Position: Cash and equivalents constituted 54.1% of total assets in 2024, down from 92.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 44.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 44.3% of total assets.
Iterum Therapeutics PLC Competitors by Total Assets
Key competitors of Iterum Therapeutics PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Iterum Therapeutics PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.13 | 0.85 | 0.51 |
| Quick Ratio | 1.96 | 0.86 | 0.60 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.30 Million | $-2.85 Million | $-20.23 Million |
Iterum Therapeutics PLC - Advanced Valuation Insights
This section examines the relationship between Iterum Therapeutics PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.03 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 69.8% |
| Total Assets | $44.59 Million |
| Market Capitalization | $3.20 Million USD |
Valuation Analysis
Below Book Valuation: The market values Iterum Therapeutics PLC's assets below their book value (0.07x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Iterum Therapeutics PLC's assets grew by 69.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Iterum Therapeutics PLC (2016–2024)
The table below shows the annual total assets of Iterum Therapeutics PLC from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $44.59 Million | +69.83% |
| 2023-12-31 | $26.26 Million | -60.71% |
| 2022-12-31 | $66.83 Million | -26.97% |
| 2021-12-31 | $91.51 Million | +179.06% |
| 2020-12-31 | $32.79 Million | +27.34% |
| 2019-12-31 | $25.75 Million | -73.69% |
| 2018-12-31 | $97.87 Million | +109.32% |
| 2017-12-31 | $46.76 Million | +73.71% |
| 2016-12-31 | $26.92 Million | -- |
About Iterum Therapeutics PLC
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with lim… Read more